Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis

Experimental Hematology

Volumn 39, Issue 8, 2011, Pages

  Wasag, Bartosz ^a,b   Niedoszytko, Marek ^a   Piskorz, Anna ^a   Lange, Magdalena ^a   Renke, Joanna ^c   Jassem, Ewa ^a   Biernat, Wojciech ^a   Debiec Rychter, Maria ^b   Limon, Janusz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b UNIVERSITY OF LEUVEN   (Belgium)

^c Children's Hospital Polanki   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ADRENALIN; CD2 ANTIGEN; DASATINIB; GLUCOCORTICOID; HISTAMINE H1 RECEPTOR ANTAGONIST; IMATINIB; INTERLEUKIN 2 RECEPTOR ALPHA; TRYPTASE;

ADULT; ARTICLE; BLOOD SAMPLING; BONE MARROW BIOPSY; CASE REPORT; CELL PROLIFERATION; CELL SURVIVAL; CHILD; CYTOLOGY; FAMILIAL DISEASE; FEMALE; FLOW CYTOMETRY; GENE; GENE MUTATION; HISTOPATHOLOGY; HUMAN; HUMAN CELL; MALE; MISSENSE MUTATION; N822I GENE; ONCOGENE C KIT; ORAL BIOPSY; PLASMID; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; QUALITY OF LIFE; SIGNAL TRANSDUCTION; TREATMENT RESPONSE; URINALYSIS; URTICARIA PIGMENTOSA;

EID: 79960629726     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2011.05.009     Document Type: Article

References (24)

1. Valent P., Akin C., Escribano L., et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest 2007, 37:435-453.
2. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108:2366-2372.
3. Wilson T.M., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96:459-463.
4. Beghini A., Tibiletti M.G., Roversi G., et al. Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. Cancer 2001, 92:657-662.
5. Hartmann K., Wardelmann E., Ma Y., et al. Novel germline mutation of KIT associated with familial gastrointestinal stromal tumors and mastocytosis. Gastroenterology 2005, 129:1042-1046.
6. Tang X., Boxer M., Drummond A., Ogston P., Hodgins M., Burden A.D. A germline mutation in KIT in familial diffuse cutaneous mastocytosis. J Med Genet 2004, 41:e88.
7. Zhang L.Y., Smith M.L., Schultheis B., et al. A novel K509I mutation of KIT identified in familial mastocytosis-in vitro and in vivo responsiveness to imatinib therapy. Leuk Res 2006, 30:373-378.
8. Bodemer C., Hermine O., Palmérini F., et al. Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. J Invest Dermatol 2010, 130:804-815.
9. Lombardo L.J., Lee F.Y., Chen P., et al. Discovery of N-(2-chloro-6-methyl-phenyl)-2-(6-(4-(2-hydroxyethyl)-piperazin-1-yl)-2-methylpyrimidin-4-ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. J Med Chem 2004, 47:6658-6661.
10. Dewaele B., Wasag B., Cools J., et al. Activity of dasatinib, a dual SRC/ABL kinase inhibitor, and IPI-504, a heat shock protein 90 inhibitor, against gastrointestinal stromal tumor-associated PDGFRAD842V mutation. Clin Cancer Res 2008, 14:5749-5758.
11. Shah N.P., Lee F.Y., Luo R., Jiang Y., Donker M., Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood 2006, 108:286-291.
12. Mital A., Piskorz A., Lewandowski K., Wasaogonekg B., Limon J., Hellmann A. A case of mast cell leukemia with exon 9 KIT mutation and good response to imatinib. Eur J Haematol 2011, 86:531-535.
13. Debiec-Rychter M., Cools J., Dumez H., et al. Mechanisms of resistance to imatinib mesylate in gastrointestinal stromal tumors and activity of the PKC412 inhibitor against imatinib-resistant mutants. Gastroenterology 2005, 128:270-279.
14. Kemmer K., Corless C.L., Fletcher J.A., et al. KIT mutations are common in testicular seminomas. Am J Pathol 2004, 164:305-313.
15. Lux M.L., Rubin B.P., Biase T.L., et al. KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. Am J Pathol 2000, 156:791-795.
16. Shimada A., Taki T., Kubota C., et al. N822 mutation of KIT gene was frequent in pediatric acute myeloid leukemia patients with t(8;21) in Japan: a study of the Japanese childhood AML cooperative study group. Leukemia 2007, 21:2218-2219.
17. Thalheimer A., Schlemmer M., Bueter M., et al. Familial gastrointestinal stromal tumors caused by the novel KIT exon 17 germline mutation N822Y. Am J Surg Pathol 2008, 32:1560-1565.
18. McDonnell K., Betz B., Fullen D., Lao C.D. V559A and N822I double KIT mutant melanoma with predictable response to imatinib?. Pigment Cell Melanoma Res 2011, 24:390-392.
19. Carballo M., Roig I., Aguilar F., et al. Novel c-KIT germline mutation in a family with gastrointestinal stromal tumors and cutaneous hyperpigmentation. Am J Med Genet A 2005, 132:361-364.
20. Yang Y., Létard S., Borge L., et al. Pediatric mastocytosis-associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations. Blood 2010, 116:1114-1123.
21. Beghini A., Bellini M., Magnani I., et al. STI 571 inhibition effect on KITAsn822Lys-mediated signal transduction cascade. Exp Hematol 2005, 33:682-688.
22. Guo T., Agaram N.P., Wong G.C., et al. Sorafenib inhibits the imatinib-resistant KITT670I gatekeeper mutation in gastrointestinal stromal tumor. Clin Cancer Res 2007, 13:4874-4881.
23. Verstovsek S., Tefferi A., Cortes J., et al. Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. Clin Cancer Res 2008, 14:3906-3915.
24. Ustun C., Corless C.L., Savage N., et al. Chemotherapy and dasatinib induce long-term hematologic and molecular remission in systemic mastocytosis with acute myeloid leukemia with KIT D816V. Leuk Res 2009, 33:735-741.